146 related articles for article (PubMed ID: 3493845)
41. Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages.
Nakajima H; Fujiwara H; Takai Y; Izumi Y; Sano S; Tsuchida T; Hamaoka T
J Immunol; 1985 Sep; 135(3):2199-205. PubMed ID: 3894520
[TBL] [Abstract][Full Text] [Related]
42. Effector cell analysis of tumor cell rejection in vivo in two syngeneic tumor systems exhibiting distinct in vitro cytotoxic mechanisms.
Fukuzawa M; Fujiwara H; Yoshioka T; Itoh K; Hamaoka T
Gan; 1984 Oct; 75(10):912-9. PubMed ID: 6334626
[TBL] [Abstract][Full Text] [Related]
43. Feasibility of UV-inactivated vaccinia virus in the modification of tumor cells for augmentation of their immunogenicity.
Wakamiya N; Wang YL; Imai H; Gu HX; Ueda S; Kato S
Cancer Immunol Immunother; 1986; 23(2):125-9. PubMed ID: 3779714
[TBL] [Abstract][Full Text] [Related]
44. Tolerance induction of alloreactivity by portal venous inoculation with allogeneic cells followed by the injection of cyclophosphamide. I. Specific suppression of alloreactive cytotoxic and delayed-type hypersensitivity responses as well as allograft rejection.
Qian JH; Kokudo S; Sato S; Hamaoka T; Fujiwara H
Transplantation; 1987 Apr; 43(4):538-43. PubMed ID: 3495052
[TBL] [Abstract][Full Text] [Related]
45. T-cell responses induced by the parenteral injection of antigen-modified syngeneic cells. II. Mechanisms, specificity, and cellular analysis of 2,4,6-trinitrophenol (TNP)-specific cytolytic response priming by intravenous versus subcutaneous injection with TNP-modified syngeneic cells.
Miller SD; Butler LD; Cleveland RP; Moorhead JW; Claman HN; Chiller JC
Cell Immunol; 1983 Dec; 82(2):378-93. PubMed ID: 6197193
[TBL] [Abstract][Full Text] [Related]
46. Augmentation of the generation of cytotoxic T lymphocytes against syngeneic tumor cells by recombinant human tumor necrosis factor.
Nakano K; Okugawa K; Furuichi H; Matsui Y; Sohmura Y
Cell Immunol; 1989 Apr; 120(1):154-64. PubMed ID: 2649256
[TBL] [Abstract][Full Text] [Related]
47. Differential ability of tumor-unique and cross-reactive antigen(s) on two murine hepatoma cell lines to induce Lyt-1+2- T cells responsible for in vivo protective immunity.
Shima J; Yoshioka T; Kosugi A; Ogata M; Fujiwara H; Hamaoka T; Ueda S; Kato S
Biken J; 1987 Mar; 30(1):1-8. PubMed ID: 2445335
[TBL] [Abstract][Full Text] [Related]
48. Long-lasting skin allograft tolerance in adult mice induced across fully allogeneic (multimajor H-2 plus multiminor histocompatibility) antigen barriers by a tolerance-inducing method using cyclophosphamide.
Mayumi H; Good RA
J Exp Med; 1989 Jan; 169(1):213-38. PubMed ID: 2642528
[TBL] [Abstract][Full Text] [Related]
49. Tumor immunity to murine plasma cell tumors. III. Detection of common and unique tumor-associated antigens on BALB/c, C3H, and NZB plasmacytomas by in vivo and in vitro induction of tumor-immune responses.
Burton RC; Warner NL
J Natl Cancer Inst; 1977 Mar; 58(3):701-9. PubMed ID: 300112
[TBL] [Abstract][Full Text] [Related]
50. [Significance of priming of hosts with virus in the tumor-specific immunotherapy model utilizing virus-reactive helper T cell activity].
Shimizu Y; Hasumi K; Masubuchi K; Okudaira Y
Nihon Gan Chiryo Gakkai Shi; 1989 May; 24(5):1007-14. PubMed ID: 2528599
[TBL] [Abstract][Full Text] [Related]
51. The augmentation of tumor-specific immunity by virus help. I. Demonstration of vaccinia virus-reactive helper T cell activity involved in enhanced induction of cytotoxic T lymphocyte and antibody responses.
Fujiwara H; Shimizu Y; Takai Y; Wakamiya N; Ueda S; Kato S; Hamaoka T
Eur J Immunol; 1984 Feb; 14(2):171-5. PubMed ID: 6199215
[TBL] [Abstract][Full Text] [Related]
52. Preferential generation of killer or helper T-lymphocyte activity directed to the tumour-associated transplantation antigens.
Fujiwara H; Hamaoka T; Teshima K; Aoki H; Kitagawa M
Immunology; 1976 Aug; 31(2):239-48. PubMed ID: 1085283
[TBL] [Abstract][Full Text] [Related]
53. The mechanism of tolerance induction in thymus-derived lymphocytes; I. intracellular inactivation of hapten-reactive helper T lymphocytes by hapten-nonimmunogenic copolymer of D-amino acids.
Hamaoka T; Yamaskita U; Takami T; Kitagawa M
J Exp Med; 1975 Jun; 141(6):1308-28. PubMed ID: 47899
[TBL] [Abstract][Full Text] [Related]
54. Studies on the induction of tolerance to alloantigens. I. The abrogation of potentials for delayed-type-hypersensitivity response to alloantigens by portal venous inoculation with allogeneic cells.
Qian J; Hashimoto T; Fujiwara H; Hamaoka T
J Immunol; 1985 Jun; 134(6):3656-61. PubMed ID: 2580893
[TBL] [Abstract][Full Text] [Related]
55. Regulatory functions of hapten-reactive helper and suppressor T lymphocytes. I. Detection and characterization of hapten-reactive suppressor T-cell activity in mice immunized with hapten-isologous protein conjugate.
Yamamoto H; Hamaoka T; Yoshizawa M; Kuroki M; Kitagawa M
J Exp Med; 1977 Jul; 146(1):74-90. PubMed ID: 68994
[TBL] [Abstract][Full Text] [Related]
56. Cell-mediated immune responses to syngeneic ultraviolet-induced tumours. V. Assessment of accessory and antigen-presenting cell capabilities of normal and ultraviolet-irradiated mice in the generation of anti-tumour cytotoxic effector cells in vitro.
Lynch DH; Gurish MF; Daynes RA
Immunology; 1982 Sep; 47(1):49-59. PubMed ID: 6981587
[TBL] [Abstract][Full Text] [Related]
57. The nature of tolerance in adult recipient mice made tolerant of alloantigens with supralethal irradiation followed by syngeneic bone marrow cell transplantation plus injection of F1 spleen cells.
Tomita Y; Himeno K; Mayumi H; Tokuda N; Nomoto K
Transplantation; 1989 Jun; 47(6):1021-9. PubMed ID: 2660340
[TBL] [Abstract][Full Text] [Related]
58. Studies in the enhancement of tumour immunity by coupling strong antigens to tumour cells ('heterogenization of tumours'). Helper T cell clones against PPD help other T cells mount anti-tumour responses to PPD-coupled tumour cells.
Sia DY; Lachmann PJ; Leung KN
Immunology; 1984 Apr; 51(4):755-63. PubMed ID: 6200428
[TBL] [Abstract][Full Text] [Related]
59. Enhancement of effector cell activities in mice bearing syngeneic plasmacytoma X5563 by a biological response modifier, PSK.
Matsunaga K; Iijima H; Aota M; Oguchi Y; Fujii T; Yoshikumi C; Nomoto K
J Clin Lab Immunol; 1992 Jan; 37(1):21-37. PubMed ID: 1339233
[TBL] [Abstract][Full Text] [Related]
60. [Future perspectives on tumor-specific immunotherapy using hapten-reactive T cell activity].
Hamaoka T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):886-96. PubMed ID: 2786376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
